- Business Wire•6 hours ago
Verastem, Inc. , focused on discovering and developing drugs to treat cancer, today announced the presentation of results from the DYNAMO® study, a Phase 2 clinical trial evaluating the safety and efficacy of duvelisib in patients with indolent non-Hodgkin lymphoma that is double refractory to both rituximab and chemotherapy, at the American Society of Hematology 2016 Annual Meeting held December 3-6, ...
- Associated Press•28 days ago
On a per-share basis, the Needham, Massachusetts-based company said it had a loss of 21 cents. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
VSTM : Summary for Verastem, Inc. - Yahoo Finance
Verastem, Inc. (VSTM)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
|Day's Range||1.07 - 1.16|
|52 Week Range||1.05 - 2.06|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-1.08|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|